Related Experiment Video
Updated: Jan 20, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[EGFR gene mutation status among lung cancer patients in China]
Qi Li1, Ya-li Zhao, Hao-jie Hao
1Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing 100853, China.
Objective:
To investigate EGFR gene mutations in non-small cell lung cancers (NSCLCs) and their correlation with clinicopathologic features and clinical characteristics in Chinese NSCLC patients.
Methods:
To analyse EGFR mutations of exons 19 and 21 in NSCLCs by PCR amplification and sequencing.
Results:
Somatic mutations in TK domain of EGFR were found in 13 cases (17.3%), the majority of mutations were in-frame exon 19 (9.3%) and 6 cases missense mutation in exon 21 (8.0%). The mutation rate was significantly higher in adenocarcinoma (12/31, 38.7%), than in bronchioloalveolar cancer (1/10, 10. 0%), adeno-squamous carcinoma (0/5), pulmonary blastoma (0/2), large cell carcinoma (0/1) and squamous cell carcinoma (0/26). Moreover, mutations were more frequently observed in females (30.0%) than in males (8.9%), and significantly higher in non-smokers (28.2%) than in smokers (5.6%).
Conclusion:
EGFR gene mutation is significantly higher related to adenocarcinomas, females and never-smokers. The results may suggest that a lager portion of adenocarcinomas in Chinese patients, females and non-smokers could be associated with favorable response to gefinib.
Related Concept Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Mutation, Gene Flow, and Genetic Drift

